ArticleBMC gastroenterology2026
Application of transjugular liver biopsy in pediatric living donor liver transplantation.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the safety and diagnostic utility of transjugular liver biopsy (TJLB) in pediatric patients with contraindications to percutaneous biopsy after living donor liver transplantation (LDLT).
methodsThis was a single-center retrospective case series of 22 pediatric LDLT recipients (7 females) who underwent TJLB at Tianjin First Central Hospital between January 2021 and June 2024. Key cohort risks included preoperative coagulation dysfunction (INR > 1.5, n = 9), thrombocytopenia (platelet count < 50 × 10⁹/L, n = 7), and ascites (n = 12). Outcomes analyzed included technical/clinical success rates and postoperative complications.
resultsTechnical and clinical success rates were both 100% (95% CI: 85.2%–100.0%). No severe complications occurred; only 1 case (4.5%, 95% CI: 0.1%–22.8%) of postoperative abdominal pain (managed with oral analgesics) was reported. All specimens were diagnostically adequate.
conclusionTJLB demonstrates encouraging safety and diagnostic value in this small single-center cohort of high-risk pediatric LDLT recipients with coagulopathy, thrombocytopenia, or ascites. It provides a reliable alternative for patients with percutaneous biopsy contraindications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.